Repare Therapeutics Inc. has announced a transaction with DCx Biotherapeutics Corporation, in which DCx will in-license Repare's discovery platform, including specific program intellectual property. The transaction also involves DCx acquiring rights to Repare's proprietary CRISPR, bioinformatics, and machine learning platforms, collectively known as the MuSic™ Platform, for identifying surfaceome targets in tumors. Additionally, DCx will retain talent, acquire lease rights to laboratory facilities in Montreal, and obtain laboratory equipment from Repare. This deal aims to accelerate the development of Multi-Modal Antibody Drug Conjugates (MM-ADCs) targeting genetically-defined cancers. Repare will receive upfront and near-term cash payments, equity in DCx, and milestones and royalties for products developed with the acquired programs and targets.